Study identifies potential RAS inhibitor-immunotherapy strategy for pancreatic cancer
Researchers have identified a new strategy for treating pancreatic cancer by combining RAS inhibitors with an AI-designed immune-stimulating agent called 21h10. This combination has shown the potential to create a durable immune response in mouse models, offering a promising path for future human clinical trials.
Why it matters
Pancreatic cancer is notoriously difficult to treat with immunotherapy; this research provides a potential breakthrough in making these tumors responsive to immune-based therapies.
edited by Lisa Lock , reviewed by Andrew Zinin
This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:
Add as preferred source Stephanie K. Dougan, PhD, of Dana-Farber Cancer Institute co-led research identifying potential RAS inhibitor-immunotherapy strategy for pancreatic cancer. Credit: Dana-Farber Cancer Institute Pancreatic cancer does not respond to most immunotherapies, but RAS inhibitors could alter tumors to make them more sensitive to a novel immunotherapeutic approach. In pancreatic tumors with RAS mutations, RAS inhibitors cause massive cell death and reduce immunosuppression. These changes tend to be temporary because tumors develop resistance to the therapy.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in